celecoxib has been researched along with Cancer of Stomach in 65 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the long-term risk of gastroduodenal ulcer and cardiovascular events induced by celecoxib in a population-based, randomized, double-blind, placebo-controlled study." | 9.13 | Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. ( Feng, GS; Lam, SK; Li, J; Li, JY; Liu, WD; Ma, JL; Pan, KF; Shen, L; Wong, BC; Xia, HH; You, WC; Zhang, L; Zhang, XD, 2008) |
| "Celecoxib combined with octreotide significantly promoted necrosis in gastric adenocarcinoma through the induction of apoptosis and the reduction of MVD." | 9.12 | Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide. ( Chen, ZX; Huang, MH; Huang, MT; Liu, R; Tang, CW; Wang, CH; Wei, B; Zhang, B, 2007) |
| "Celecoxib can enhance apoptosis of GC cell by induction of NAG-1 gene transcription in human." | 6.74 | [Celecoxib inhibits gastric adenocarcinoma growth via inducing expression of human nonsteroidal anti-inflammatory drug activated gene]. ( Chen, JP; Ciren, YJ; Tang, CW; Wang, R; Yang, JL; Zhang, B, 2009) |
| "To evaluate the long-term risk of gastroduodenal ulcer and cardiovascular events induced by celecoxib in a population-based, randomized, double-blind, placebo-controlled study." | 5.13 | Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. ( Feng, GS; Lam, SK; Li, J; Li, JY; Liu, WD; Ma, JL; Pan, KF; Shen, L; Wong, BC; Xia, HH; You, WC; Zhang, L; Zhang, XD, 2008) |
| "Celecoxib combined with octreotide significantly promoted necrosis in gastric adenocarcinoma through the induction of apoptosis and the reduction of MVD." | 5.12 | Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide. ( Chen, ZX; Huang, MH; Huang, MT; Liu, R; Tang, CW; Wang, CH; Wei, B; Zhang, B, 2007) |
| "To see whether celecoxib prevents gastric cancer occurrence by disrupting the progression of chronic gastritis into gastric carcinoma through its inhibition of the migration of CD133-positive cells, one of the surface markers of bone marrow-derived cells, in Helicobacter pylori-infected gerbils." | 3.76 | Celecoxib inhibits CD133-positive cell migration via reduction of CCR2 in Helicobacter pylori-infected Mongolian gerbils. ( Futagami, S; Gudis, K; Hamamoto, T; Horie, A; Kawagoe, T; Nagoya, H; Sakamoto, C; Shimpuku, M; Shindo, T, 2010) |
| " We recently showed that NSAIDs such as indomethacin and celecoxib have direct cytotoxicity (ability to induce necrosis and apoptosis in gastric mucosal cells) due to their membrane permeabilizing activities, which is involved in NSAID-induced gastric lesions." | 3.76 | Low direct cytotoxicity of loxoprofen on gastric mucosal cells. ( Arai, Y; Ishihara, T; Kimoto, A; Mizushima, T; Okamoto, Y; Otsuka, M; Suemasu, S; Tanaka, K; Yamakawa, N; Yokomizo, K, 2010) |
| "Celecoxib combined with chemotherapy offers more clinical benefits for COX-2 positive advanced gastric cancer patients." | 2.90 | A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study. ( Chen, Z; Guan, Q; Guo, Q; Li, Q; Liu, M; Wang, J; Wang, Y; Ye, Y; Zhou, Y, 2019) |
| "In total, 240 gastric cancer patients undergoing radical gastrectomy followed by adjuvant chemotherapy were randomly assigned into 2 groups." | 2.84 | Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer. ( Chen, Z; Guo, Q; Ji, R; Liu, X; Lu, L; Wang, Y; Yuan, H; Zhou, Y, 2017) |
| "Celecoxib can enhance apoptosis of GC cell by induction of NAG-1 gene transcription in human." | 2.74 | [Celecoxib inhibits gastric adenocarcinoma growth via inducing expression of human nonsteroidal anti-inflammatory drug activated gene]. ( Chen, JP; Ciren, YJ; Tang, CW; Wang, R; Yang, JL; Zhang, B, 2009) |
| "Fifty nine gastric cancer patients were randomly divided into two groups: Surgery group (n = 22), in which patients underwent surgical resection after diagnosis, and Celecoxib + Surgery group (n = 37), in which patients received oral Celecoxib 200 mg twice daily for 7 days before curative resection." | 2.73 | Effect of celecoxib on E-cadherin, VEGF, Microvessel density and apoptosis in gastric cancer. ( Honghua, L; Ning, C; Qiao, L; Ran, J; Tang, C; Wu, J; Xingwen, L; Zhou, Y, 2007) |
| "Fifty nine gastric cancer patients were randomly divided into 2 groups: celecoxib group (n = 37) and control group (n = 22)." | 2.73 | [Celecoxib induces apoptosis and inhibits angiogenesis in gastric cancer]. ( Lu, H; Lu, JR; Ran, JT; Tang, CW; Wu, J; Yang, GD; Zhou, YN, 2008) |
| "The GC cells from the resected gastric cancer specimens were isolated by immunomagnetic separation." | 2.72 | [The inhibitive effects of celecoxib combined with octreotide on the metastasis of human gastric cancer in vivo]. ( Chen, ZX; Huang, MH; Huang, MT; Tang, CW; Wang, CH; Wei, B; Zhang, B, 2006) |
| "Capecitabine is an oral 5-fluorouracil (5-FU) prodrug that is more convenient than using infusional 5-FU, appears to have a similar therapeutic profile, and can be combined with daily irradiation." | 2.42 | COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas. ( Rich, TA; Shepard, R, 2003) |
| "Gastric cancer is the fourth most common cancer in the world." | 1.43 | Dimethyl celecoxib sensitizes gastric cancer cells to ABT-737 via AIF nuclear translocation. ( Li, Y; Lin, N; Wang, L; Wang, M; Yan, Y; Zeng, J; Zhang, B; Zhang, D, 2016) |
| "Celecoxib (COX-2 inhibitor) inhibits gastric cancer cell proliferation, but with low treatment efficacy, limiting its applications." | 1.42 | Anti-LeY antibody enhances therapeutic efficacy of celecoxib against gastric cancer by downregulation of MAPKs/COX-2 signaling pathway: correlation with clinical study. ( Aziz, F; Wang, X; Yan, Q; Yang, X, 2015) |
| "Celecoxib was more effective in SGC-7901/DDP cells with a lower inhibitory concentration compared to that in SGC-7901 cells, supporting such a cyclooxygenase-2-dependent drug resistance in SGC-7901/DDP cells." | 1.42 | Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2. ( Lv, QZ; Shen, FM; Xu, HB, 2015) |
| "As4S4 in combination with JQ1, cisplatin, irinotecan or celecoxib showed enhanced cytotoxic effect on gastric and colon cancer cells, indicating the potential application of these novel drug combinations as part of treatment strategy that warrants further investigation." | 1.42 | Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth. ( Chen, S; Pan, M; Tong, Y; Zhang, L; Zhang, X, 2015) |
| "In two gastric cancer cell lines, MGC-803 and SGC-7901, S100P expression was knocked down by a lentiviral short hairpin delivery system." | 1.40 | Knockdown of S100P by lentiviral-mediated RNAi promotes apoptosis and suppresses the colony-formation ability of gastric cancer cells. ( Hu, H; Shi, X; Tang, W; Zhang, Q, 2014) |
| "The HERG mRNA, protein and current in gastric cancer cells transfected with or without COX-2 antisense vector were measured by RT-PCR, Western blot and patch-clamp, respectively." | 1.40 | The mechanism of COX-2 regulating HERG channel in gastric cancer cells. ( Guo, XZ; Lin, H; Ren, LN; Shao, XD, 2014) |
| " In some tumor models, the combination of celecoxib with chemotherapy agents has shown synergistic antitumor effect; however, the effect of celecoxib combination with tegafur/gimeracil/oteracil potassium on the malignant biological behaviors of gastric cancer in nude mice is unclear." | 1.40 | Effect of celecoxib combined with chemotherapy drug on malignant biological behaviors of gastric cancer. ( Dai, K; Fang, M; Lu, Z; Luo, J; Luo, Z; Meng, C; Zhang, S; Zhou, X, 2014) |
| "pylori-induced gastric cancer cell motility and invasion." | 1.39 | Celecoxib inhibits Helicobacter pylori-induced invasion of gastric cancer cells through an adenine nucleotide translocator-dependent mechanism. ( Fan, L; Fang, D; Guo, GJ; Lan, C; Wan, S; Wang, J; Wang, R; Yang, L; Yang, S; Zhang, Y, 2013) |
| "A xenograft tumor model of gastric cancer was established subcutaneously in nude mice." | 1.39 | [Inhibitive effect of celecoxib combined with tegafur gimeracil oteracil potassium on the growth of xenograft tumor of gastric cancer in nude mice]. ( Chen, X; Luo, Z; Meng, C, 2013) |
| "hTERT was depleted in gastric and cervical cancer cells using small interfering RNA (siRNA) and analysed for COX2 expression using quantitative PCR and immunoblotting." | 1.39 | Telomerase reverse transcriptase inhibition stimulates cyclooxygenase 2 expression in cancer cells and synergizes with celecoxib to exert anti-cancer effects. ( Björkholm, M; Jia, J; Li, B; Liang, X; Liu, T; Xu, D, 2013) |
| "Celecoxib was able to restrain proliferation and induce apoptosis in a dose- and time- dependent manner, inducing G0/G1 cell cycle arrest, release of cytochrome C into the cytosol, and cleavage of pro-caspase-9 into its active form." | 1.39 | Effects of celecoxib on cycle kinetics of gastric cancer cells and protein expression of cytochrome C and caspase-9. ( Han, Z; Ma, YJ; Niu, XP; Wang, YJ; Yang, L, 2013) |
| "Human gastric cancer cell line SGC-7901 was cultured and treated with different concentration of AG1478 and celecoxib, the proliferation of SGC-7901 cells was determined by MTT." | 1.36 | [Effects of EGFR inhibitor AG1478 in combination with celecoxib on the growth of gastric cancer cells]. ( Li, RK; Liao, J; Qiang, O; Wang, CH, 2010) |
| "pylori-infected MGs developed gastric cancer." | 1.35 | Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model. ( Chang, LL; Hu, HM; Jan, CM; Kuo, CH; Tsai, PY; Wang, JY; Wang, WM; Wu, DC; Wu, IC; Yang, SF, 2009) |
| "Immunohistochemistry on TMAs of 178 gastric cancers showed no correlation between COX-2 and E-cadherin expression in the conventional or early gastric cancer groups." | 1.35 | Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines. ( de Leng, WW; Leguit, RJ; Maciejewski, R; Milne, AN; Morsink, FH; Offerhaus, GJ; Polkowski, WP; Sitarz, R, 2009) |
| "Celecoxib prevented gastric cancer in MNU-pretreated H." | 1.35 | Celecoxib inhibits apurinic/apyrimidinic endonuclease-1 expression and prevents gastric cancer in Helicobacter pylori-infected mongolian gerbils. ( Crowe, SE; Futagami, S; Gudis, K; Hamamoto, T; Horie, A; Kawagoe, T; Kusunoki, M; Miyake, K; Sakamoto, C; Shindo, T; Suzuki, K; Tsukui, T, 2008) |
| "The anti-cancer effects of celecoxib on gastric cancer cells might be partly mediated by downregulation of Akt, GSK3beta, FKHR, and upregulation of caspase-9, in the mitochondrial apoptotic pathway." | 1.35 | Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling. ( Ahn, DW; Cho, SJ; Jung, HC; Kim, CH; Kim, JS; Kim, N; Lee, KS; Lee, MK; Park, JH; Song, IS, 2009) |
| "The anticancer effects of celecoxib on gastric cancer cells appear to be mediated by cell-cycle arrest and apoptosis, and not by COX-2 or PGE(2) suppression alone." | 1.34 | The anti-cancer effect of COX-2 inhibitors on gastric cancer cells. ( Cho, SJ; Jung, HC; Kim, JS; Kim, N; Song, IS, 2007) |
| "To study the effects of two specific cyclooxygenase inhibitors (SCI), rofecoxib and celecoxib, combined with chemotherapeutic drugs 5-Fu, DDP and VP-16 on gastric cancer cell line BGC-823, and to evaluate whether specific cyclooxygenase inhibitors can be used as a synergetic agent in chemotherapy." | 1.34 | [Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro]. ( Chen, XM; Feng, JX; Wang, YJ; Zhang, X; Zhu, FS, 2007) |
| "With treatment with celecoxib, PGE(2) levels, the gastric mucosal thickness, and the number of total gastric cells per gastric gland of ACT-GAS mice were significantly decreased." | 1.33 | Involvement of cyclooxygenase-2 in gastric mucosal hypertrophy in gastrin transgenic mice. ( Chiba, T; Fukui, H; Kanda, N; Kawada, M; Konda, Y; Nakajima, T; Sawabu, T; Seno, H; Takeuchi, T; Uenoyoma, Y, 2006) |
| "The incidences of gastric cancer were 0% in group A, 75% in group B, 68." | 1.32 | Chemoprevention of gastric cancer by celecoxib in rats. ( Bai, AH; Hu, PJ; Leung, WK; Lin, HL; Sung, JJ; Tang, BD; Yu, J; Zeng, ZR, 2004) |
| "Celecoxib combined with octreotide may enhance inhibition of growth of multidrug resistant human gastric cancer cells." | 1.32 | [Inhibitory effects of celecoxib combined with octreotide on growth of multidrug resistant human gastric cancer cell line SGC7901/ADR]. ( Qiang, O; Tang, CW; Wang, CH; Zheng, WB, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 34 (52.31) | 29.6817 |
| 2010's | 30 (46.15) | 24.3611 |
| 2020's | 1 (1.54) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, G | 1 |
| Zhang, J | 1 |
| Cao, T | 1 |
| Zhu, H | 1 |
| Shi, Y | 1 |
| Lin, XM | 1 |
| Li, S | 1 |
| Zhou, C | 1 |
| Li, RZ | 1 |
| Wang, H | 1 |
| Luo, W | 1 |
| Huang, YS | 1 |
| Chen, LK | 1 |
| Cai, JL | 1 |
| Wang, TX | 1 |
| Zhang, QH | 1 |
| Cao, H | 1 |
| Wu, XP | 1 |
| Guo, Q | 2 |
| Liu, X | 1 |
| Lu, L | 1 |
| Yuan, H | 1 |
| Wang, Y | 2 |
| Chen, Z | 2 |
| Ji, R | 2 |
| Zhou, Y | 3 |
| Li, Q | 3 |
| Wang, J | 3 |
| Liu, M | 2 |
| Ye, Y | 1 |
| Guan, Q | 1 |
| Lan, C | 1 |
| Yang, L | 2 |
| Fan, L | 1 |
| Zhang, Y | 3 |
| Guo, GJ | 1 |
| Wan, S | 1 |
| Yang, S | 1 |
| Wang, R | 2 |
| Fang, D | 1 |
| Meng, C | 2 |
| Chen, X | 1 |
| Luo, Z | 2 |
| Liu, T | 1 |
| Liang, X | 1 |
| Li, B | 1 |
| Björkholm, M | 1 |
| Jia, J | 1 |
| Xu, D | 1 |
| Wang, YJ | 2 |
| Niu, XP | 1 |
| Han, Z | 1 |
| Ma, YJ | 1 |
| Nakamura, M | 1 |
| Takahashi, T | 1 |
| Matsui, H | 1 |
| Takahashi, S | 1 |
| Murayama, SY | 1 |
| Suzuki, H | 2 |
| Tsuchimoto, K | 1 |
| Li, CM | 1 |
| Chen, ZF | 1 |
| Guo, QH | 1 |
| Zhang, HL | 1 |
| Zhou, YN | 3 |
| Zhang, Q | 1 |
| Hu, H | 1 |
| Shi, X | 1 |
| Tang, W | 1 |
| Xiang, HG | 1 |
| Xie, X | 1 |
| Hu, FQ | 1 |
| Xiao, HB | 1 |
| Zhang, WJ | 1 |
| Chen, L | 1 |
| Shao, XD | 1 |
| Guo, XZ | 1 |
| Ren, LN | 1 |
| Lin, H | 1 |
| Zhang, XQ | 1 |
| Sun, XE | 1 |
| Liu, WD | 3 |
| Feng, YG | 1 |
| Zhang, HM | 1 |
| Shi, LH | 1 |
| Sun, XN | 1 |
| Li, YQ | 1 |
| Gao, ZX | 1 |
| Aziz, F | 1 |
| Yang, X | 1 |
| Wang, X | 1 |
| Yan, Q | 1 |
| Lu, Z | 1 |
| Fang, M | 1 |
| Zhou, X | 1 |
| Dai, K | 1 |
| Zhang, S | 1 |
| Luo, J | 1 |
| Cao, Y | 1 |
| Qu, J | 1 |
| Li, C | 1 |
| Yang, D | 1 |
| Hou, K | 1 |
| Zheng, H | 1 |
| Liu, Y | 1 |
| Qu, X | 1 |
| Xu, HB | 2 |
| Shen, FM | 2 |
| Lv, QZ | 2 |
| Pan, KF | 4 |
| Zhang, L | 5 |
| Ma, JL | 4 |
| Zhou, T | 1 |
| Li, JY | 4 |
| Shen, L | 3 |
| You, WC | 4 |
| Tong, Y | 1 |
| Zhang, X | 2 |
| Pan, M | 1 |
| Chen, S | 1 |
| Zeng, HM | 1 |
| Nie, XR | 1 |
| Zhang, B | 4 |
| Yan, Y | 1 |
| Li, Y | 1 |
| Zhang, D | 1 |
| Zeng, J | 1 |
| Wang, L | 1 |
| Wang, M | 1 |
| Lin, N | 1 |
| Feng, GS | 2 |
| Wong, BC | 2 |
| Zhang, XD | 2 |
| Li, J | 2 |
| Xia, HH | 2 |
| Lam, SK | 1 |
| Kim, N | 2 |
| Kim, CH | 1 |
| Ahn, DW | 1 |
| Lee, KS | 1 |
| Cho, SJ | 2 |
| Park, JH | 1 |
| Lee, MK | 1 |
| Kim, JS | 2 |
| Jung, HC | 2 |
| Song, IS | 2 |
| Liu, H | 1 |
| Huang, P | 1 |
| Xu, X | 1 |
| Liu, J | 1 |
| Guo, C | 1 |
| Futagami, S | 4 |
| Kawagoe, T | 2 |
| Horie, A | 2 |
| Shindo, T | 4 |
| Hamamoto, T | 4 |
| Suzuki, K | 4 |
| Kusunoki, M | 3 |
| Miyake, K | 3 |
| Gudis, K | 4 |
| Tsukui, T | 3 |
| Crowe, SE | 1 |
| Sakamoto, C | 4 |
| Ran, JT | 2 |
| Tang, CW | 7 |
| Lu, JR | 1 |
| Wu, J | 2 |
| Lu, H | 2 |
| Yang, GD | 1 |
| Namba, T | 3 |
| Homan, T | 1 |
| Nishimura, T | 1 |
| Mima, S | 3 |
| Hoshino, T | 3 |
| Mizushima, T | 4 |
| Peng, J | 1 |
| Zhang, GY | 1 |
| Wang, CH | 5 |
| Zheng, WB | 2 |
| Qiang, O | 3 |
| Zhang, LJ | 1 |
| Wang, SY | 1 |
| Huo, XH | 1 |
| Zhu, ZL | 1 |
| Chu, JK | 1 |
| Ma, JC | 1 |
| Cui, DS | 1 |
| Gu, P | 1 |
| Zhao, ZR | 1 |
| Wang, MW | 1 |
| Yu, J | 4 |
| Li, HH | 1 |
| Li, XW | 1 |
| Kuo, CH | 1 |
| Hu, HM | 1 |
| Tsai, PY | 1 |
| Wu, IC | 1 |
| Yang, SF | 1 |
| Chang, LL | 1 |
| Wang, JY | 1 |
| Jan, CM | 1 |
| Wang, WM | 1 |
| Wu, DC | 1 |
| Sitarz, R | 1 |
| Leguit, RJ | 1 |
| de Leng, WW | 1 |
| Morsink, FH | 1 |
| Polkowski, WP | 1 |
| Maciejewski, R | 1 |
| Offerhaus, GJ | 1 |
| Milne, AN | 1 |
| Ciren, YJ | 1 |
| Yang, JL | 1 |
| Chen, JP | 1 |
| Shimpuku, M | 1 |
| Nagoya, H | 1 |
| Yamakawa, N | 1 |
| Suemasu, S | 1 |
| Kimoto, A | 1 |
| Arai, Y | 2 |
| Ishihara, T | 3 |
| Yokomizo, K | 1 |
| Okamoto, Y | 1 |
| Otsuka, M | 1 |
| Tanaka, K | 2 |
| Li, RK | 1 |
| Liao, J | 1 |
| Oshima, H | 1 |
| Hioki, K | 1 |
| Popivanova, BK | 1 |
| Oguma, K | 1 |
| Van Rooijen, N | 1 |
| Ishikawa, TO | 1 |
| Oshima, M | 1 |
| Lu, AP | 1 |
| Lam, S | 1 |
| Thiel, A | 1 |
| Narko, K | 2 |
| Heinonen, M | 1 |
| Hemmes, A | 1 |
| Tomasetto, C | 2 |
| Rio, MC | 2 |
| Haglund, C | 1 |
| Mäkelä, TP | 1 |
| Ristimäki, A | 2 |
| Fang, L | 1 |
| Wu, HB | 1 |
| Chen, XG | 1 |
| Saito, Y | 1 |
| Imaeda, H | 1 |
| Matsuzaki, J | 1 |
| Hirata, K | 1 |
| Tsugawa, H | 1 |
| Hibino, S | 1 |
| Kanai, Y | 1 |
| Saito, H | 1 |
| Hibi, T | 1 |
| Saukkonen, K | 1 |
| Rich, TA | 1 |
| Shepard, R | 1 |
| Hu, PJ | 4 |
| Zeng, ZR | 4 |
| Leung, WK | 2 |
| Lin, HL | 1 |
| Tang, BD | 3 |
| Bai, AH | 2 |
| Sung, JJ | 2 |
| Fu, SL | 1 |
| Wu, YL | 1 |
| Zhang, YP | 1 |
| Qiao, MM | 1 |
| Chen, Y | 2 |
| To, KF | 1 |
| Ma, PK | 1 |
| Go, MY | 1 |
| Tsutsumi, S | 2 |
| Tanaka, KI | 1 |
| Aburaya, M | 1 |
| Kanda, N | 1 |
| Seno, H | 1 |
| Kawada, M | 1 |
| Sawabu, T | 1 |
| Uenoyoma, Y | 1 |
| Nakajima, T | 1 |
| Konda, Y | 1 |
| Fukui, H | 1 |
| Takeuchi, T | 1 |
| Chiba, T | 1 |
| Wu, K | 1 |
| Bai, F | 1 |
| Zhai, H | 1 |
| Xie, H | 1 |
| Du, Y | 1 |
| Liang, J | 1 |
| Han, S | 1 |
| Lin, T | 1 |
| Fan, D | 1 |
| Ogawa, S | 1 |
| Ran, J | 1 |
| Tang, C | 2 |
| Honghua, L | 1 |
| Xingwen, L | 1 |
| Ning, C | 1 |
| Qiao, L | 1 |
| Pang, RP | 1 |
| Zhou, JG | 1 |
| Li, XY | 1 |
| Chen, W | 1 |
| Chen, MH | 1 |
| Huang, MT | 2 |
| Chen, ZX | 2 |
| Wei, B | 2 |
| Huang, MH | 2 |
| Hiratsuka, T | 2 |
| Ueki, N | 2 |
| Tatsuguchi, A | 1 |
| Shinji, Y | 1 |
| Wada, K | 1 |
| Zhu, FS | 1 |
| Chen, XM | 1 |
| Feng, JX | 1 |
| Huang, L | 1 |
| Wang, C | 1 |
| Zheng, W | 1 |
| Liu, R | 2 |
| Yang, J | 1 |
| Zhao, Q | 1 |
| Yang, Y | 1 |
| You, QD | 1 |
| Zeng, S | 1 |
| Gu, HY | 1 |
| Lu, N | 1 |
| Qi, Q | 1 |
| Liu, W | 1 |
| Wang, XT | 1 |
| Guo, QL | 1 |
2 reviews available for celecoxib and Cancer of Stomach
| Article | Year |
|---|---|
COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2003 |
Chemopreventive effect of celecoxib in gastric cancer.
Topics: Animals; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Gastric | 2007 |
13 trials available for celecoxib and Cancer of Stomach
| Article | Year |
|---|---|
Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; | 2017 |
A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Capecitabine; Celecoxib; Chemotherapy, Adjuvant; Dis | 2019 |
Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Celecoxib; China; Clarithromycin; Cyclooxygenase 2; Cyclo | 2015 |
Alterations of Cyclooxygenase-2 Methylation Levels Before and After Intervention Trial to Prevent Gastric Cancer in a Chinese Population.
Topics: Adult; Anti-Bacterial Agents; Asian People; Celecoxib; Chromatography, High Pressure Liquid; Cycloox | 2016 |
Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention.
Topics: Adult; Cardiovascular Diseases; Celecoxib; China; Cyclooxygenase 2 Inhibitors; Dose-Response Relatio | 2008 |
[Celecoxib induces apoptosis and inhibits angiogenesis in gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Apoptosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Fe | 2008 |
Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions.
Topics: Adult; Aged; Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2009 |
[Short-term preoperative treatment of celecoxib, a selective cyclooxygenase-2 inhibitor, on E-cadherin expression in gastric carcinoma tissues].
Topics: Adenocarcinoma; Adult; Cadherins; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; | 2009 |
[Celecoxib inhibits gastric adenocarcinoma growth via inducing expression of human nonsteroidal anti-inflammatory drug activated gene].
Topics: Adenocarcinoma; Adult; Aged; Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; | 2009 |
Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Celecoxib; Clarithromycin; Cyclooxygenase 2 Inhibitors; D | 2012 |
Effect of celecoxib on E-cadherin, VEGF, Microvessel density and apoptosis in gastric cancer.
Topics: Adult; Aged; Apoptosis; Cadherins; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Female; H | 2007 |
[The inhibitive effects of celecoxib combined with octreotide on the metastasis of human gastric cancer in vivo].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Female; Humans; Male; Matrix Metal | 2006 |
Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apop | 2007 |
50 other studies available for celecoxib and Cancer of Stomach
| Article | Year |
|---|---|
Celecoxib Reverse Invasion and Metastasis of Gastric Cancer through Lnc_AC006548.28-miR-223-LAMC2 Pathway.
Topics: Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Mice; MicroRNAs; Stomach Neoplasm | 2022 |
Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer.
Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cisplatin; Cyclooxygenase 2; Dinoprosto | 2019 |
Celecoxib inhibits Helicobacter pylori-induced invasion of gastric cancer cells through an adenine nucleotide translocator-dependent mechanism.
Topics: Anoikis; Celecoxib; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2 Inhibitors; | 2013 |
[Inhibitive effect of celecoxib combined with tegafur gimeracil oteracil potassium on the growth of xenograft tumor of gastric cancer in nude mice].
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 | 2013 |
Telomerase reverse transcriptase inhibition stimulates cyclooxygenase 2 expression in cancer cells and synergizes with celecoxib to exert anti-cancer effects.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Female; Gene Knoc | 2013 |
Effects of celecoxib on cycle kinetics of gastric cancer cells and protein expression of cytochrome C and caspase-9.
Topics: Apoptosis; Blotting, Western; Caspase 9; Celecoxib; Cell Cycle; Cell Proliferation; Cyclooxygenase 2 | 2013 |
New pharmaceutical treatment of gastric MALT lymphoma: anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib.
Topics: Angiogenesis Inhibitors; Animals; Antibodies; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models | 2014 |
Celecoxib regulates apoptosis and autophagy via the PI3K/Akt signaling pathway in SGC-7901 gastric cancer cells.
Topics: Apoptosis; Autophagy; Blotting, Western; Caspase 8; Caspase 9; Celecoxib; Cell Line, Tumor; Cell Pro | 2014 |
Knockdown of S100P by lentiviral-mediated RNAi promotes apoptosis and suppresses the colony-formation ability of gastric cancer cells.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; beta Catenin; Calcium-Binding Proteins; Caspase 2; Celeco | 2014 |
Cyclooxygenase-2 inhibition as a strategy for treating gastric adenocarcinoma.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxy | 2014 |
The mechanism of COX-2 regulating HERG channel in gastric cancer cells.
Topics: Celecoxib; Cell Culture Techniques; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2014 |
Synergic effect between 5‑fluorouracil and celecoxib on hypoxic gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Bindi | 2015 |
Anti-LeY antibody enhances therapeutic efficacy of celecoxib against gastric cancer by downregulation of MAPKs/COX-2 signaling pathway: correlation with clinical study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cycl | 2015 |
Effect of celecoxib combined with chemotherapy drug on malignant biological behaviors of gastric cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxy | 2014 |
Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Celecoxib; Cell Line, Tumor; Cyclooxygenas | 2015 |
Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Caspase 3; Celecoxi | 2015 |
Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenicals; Azepines; Camptothecin; Celec | 2015 |
Celecoxib enhanced the cytotoxic effect of cisplatin in chemo-resistant gastric cancer xenograft mouse models through a cyclooxygenase-2-dependent manner.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Celecoxib; | 2016 |
Dimethyl celecoxib sensitizes gastric cancer cells to ABT-737 via AIF nuclear translocation.
Topics: Apoptosis; Apoptosis Inducing Factor; Biphenyl Compounds; Celecoxib; Cell Line, Tumor; Cell Lineage; | 2016 |
Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling.
Topics: Antineoplastic Agents; Blotting, Western; Caspase 9; Celecoxib; Cell Death; Cell Line, Tumor; Chromo | 2009 |
Anticancer effect of celecoxib via COX-2 dependent and independent mechanisms in human gastric cancers cells.
Topics: Blotting, Western; Celecoxib; Cell Proliferation; Chemoprevention; Colony-Forming Units Assay; Cycli | 2009 |
Celecoxib inhibits apurinic/apyrimidinic endonuclease-1 expression and prevents gastric cancer in Helicobacter pylori-infected mongolian gerbils.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Disease Progression; DNA-(Apurinic or Apyrimidinic Si | 2008 |
Up-regulation of S100P expression by non-steroidal anti-inflammatory drugs and its role in anti-tumorigenic effects.
Topics: Activating Transcription Factor 4; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Ste | 2009 |
[Effect of a selective COX-2 inhibitor on cell proliferation and apoptosis in human gastric cancer cell line BGC-823].
Topics: Apoptosis; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhi | 2008 |
Effects of non-cytotoxic drugs on the growth of multidrug-resistance human gastric carcinoma cell line.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Celecoxib; Cell Line, Tumor; Cel | 2009 |
Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Celecoxib; Cell Proliferation; Cyclooxygenase 2; C | 2009 |
Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines.
Topics: Adult; Age of Onset; Blotting, Western; Cadherins; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cy | 2009 |
Celecoxib inhibits CD133-positive cell migration via reduction of CCR2 in Helicobacter pylori-infected Mongolian gerbils.
Topics: AC133 Antigen; Adenocarcinoma; Animals; Antigens, CD; Blotting, Western; Celecoxib; Cell Count; Cell | 2010 |
Low direct cytotoxicity of loxoprofen on gastric mucosal cells.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; | 2010 |
[Effects of EGFR inhibitor AG1478 in combination with celecoxib on the growth of gastric cancer cells].
Topics: Celecoxib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Humans; Mitogen-Act | 2010 |
Prostaglandin E₂ signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors.
Topics: Animals; Antibodies, Neutralizing; Benzamides; Celecoxib; Cell Line; Cell Transformation, Neoplastic | 2011 |
Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice.
Topics: Adenoma; Animals; Apoptosis; Blotting, Western; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyc | 2012 |
[Survivin gene silencing inhibits the proliferation of human gastric cancer MGC-803 cells and enhances their sensitivity to celecoxib].
Topics: Celecoxib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Silencing; Humans; | 2011 |
The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells.
Topics: Base Sequence; Blotting, Western; Celecoxib; Cell Line, Tumor; Chromatin Immunoprecipitation; Cycloo | 2013 |
Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice.
Topics: Adenoma; Angiogenesis Inhibitors; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2003 |
Chemoprevention of gastric cancer by celecoxib in rats.
Topics: Analysis of Variance; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygen | 2004 |
Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer.
Topics: Animals; Apoptosis; Celecoxib; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 I | 2004 |
[Inhibitory effects of celecoxib combined with octreotide on growth of multidrug resistant human gastric cancer cell line SGC7901/ADR].
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Celecoxib; Cell Line, Tumor; Cyclooxygenase Inhibitors; | 2004 |
Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: implications on chemoprevention.
Topics: Adenocarcinoma; Animals; Apoptosis; Celecoxib; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inh | 2005 |
Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells.
Topics: Activating Transcription Factor 4; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Calc | 2006 |
Involvement of cyclooxygenase-2 in gastric mucosal hypertrophy in gastrin transgenic mice.
Topics: Animals; Apoptosis; Celecoxib; Cyclooxygenase 2; Dinoprostone; Gastric Mucosa; Gastrins; Gene Expres | 2006 |
Celecoxib could reverse the hypoxia-induced Angiopoietin-2 upregulation in gastric cancer.
Topics: Angiopoietin-2; Angiopoietins; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Line, Tumor; | 2006 |
[Prophylactic effect of a selective COX-2 inhibitor celecoxib on carcinogen-induced gastric premalignant lesions in rats].
Topics: Animals; Atrophy; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinopr | 2006 |
Up-regulation of 150-kDa oxygen-regulated protein by celecoxib in human gastric carcinoma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Calcium; Celecoxib; Cell Line, Tumor | 2007 |
Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3beta/NAG-1 pathway.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Caspase 3; Celecoxib; Cell Line, Tumor; Collagen | 2007 |
Celecoxib inhibits Cdx2 expression and prevents gastric cancer in Helicobacter pylori-infected Mongolian gerbils.
Topics: Animals; Biomarkers, Tumor; Biopsy, Needle; CDX2 Transcription Factor; Celecoxib; Disease Models, An | 2006 |
The anti-cancer effect of COX-2 inhibitors on gastric cancer cells.
Topics: Adenocarcinoma; Apoptosis; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Din | 2007 |
[Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; | 2007 |
Effects of celecoxib on the reversal of multidrug resistance in human gastric carcinoma by downregulation of the expression and activity of P-glycoprotein.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2007 |
Posttranscriptional regulation of the telomerase hTERT by gambogic acid in human gastric carcinoma 823 cells.
Topics: Celecoxib; Cell Line, Tumor; Genes, myc; Humans; Oncogene Protein v-akt; Pyrazoles; RNA Processing, | 2008 |